Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen vs Letrozole in Recurrent/Persistent Cervical SCC
NCT02482740Phase 2Unknown
- Sponsor
- Buddhist Tzu Chi General Hospital
- Start
- May 2015
- Primary completion
- Jan 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in squamous cell carcinoma of the cervix (CSCC) comparing Tamoxifen Arm with Letrozole Arm (2 arms). Primary endpoint: Response Rate at 1 year. Status: unknown.
02
Drugs
tamoxifenletrozole
03
Conditions
squamous cell carcinoma of the cervix (CSCC)
Beyond the preview
Go deeper on NCT02482740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02482740.